OBJECTIVE: Universal HIV screening is recommended but challenging to implement. Selectively targeting those at risk is thought to miss cases, but previous studies are limited by narrow risk criteria, incomplete implementation, and absence of direct comparisons. We hypothesized that targeted HIV screening, when fully implemented and using maximally broad risk criteria, could detect nearly as many cases as universal screening with many fewer tests. METHODS: This single-center cluster-randomized trial compared universal and targeted patient selection for HIV screeningin a lower prevalence urban emergency department. Patients were excluded for age (<18 and >64 years), known HIV infection, or previous approach for HIV testing that day. Targeted screening was offered for any risk indicator identified from charts, staff referral, or self-disclosure. Universal screening was offered regardless of risk. Baseline seroprevalence was estimated from consecutive deidentified blood samples. RESULTS: There were 9572 eligible visits during which the patient was approached. For universal screening, 40.8% (1915/4692) consented with 6 being newly diagnosed [0.31%, 95% confidence interval (CI): 0.13% to 0.65%]. For targeted screening, 37% (1813/4880) had no testing indication. Of the 3067 remaining, 47.4% (1454) consented with 3 being newly diagnosed (0.22%, 95% CI: 0.06% to 0.55%). Estimated seroprevalence was 0.36% (95% CI: 0.16% to 0.70%). Targeted screening had a higher proportion consenting (47.4% vs. 40.8%, P < 0.002), but a lower proportion of ED encounters with testing (29.7% vs. 40.7%, P < 0.002). CONCLUSIONS: Targeted screening, even when fully implemented with maximally permissive selection, offered no important increase in positivity rate or decrease in tests performed. Universal screening diagnosed more cases, because more were tested, despite a modestly lower consent rate.
RCT Entities:
OBJECTIVE: Universal HIV screening is recommended but challenging to implement. Selectively targeting those at risk is thought to miss cases, but previous studies are limited by narrow risk criteria, incomplete implementation, and absence of direct comparisons. We hypothesized that targeted HIV screening, when fully implemented and using maximally broad risk criteria, could detect nearly as many cases as universal screening with many fewer tests. METHODS: This single-center cluster-randomized trial compared universal and targeted patient selection for HIV screening in a lower prevalence urban emergency department. Patients were excluded for age (<18 and >64 years), known HIV infection, or previous approach for HIV testing that day. Targeted screening was offered for any risk indicator identified from charts, staff referral, or self-disclosure. Universal screening was offered regardless of risk. Baseline seroprevalence was estimated from consecutive deidentified blood samples. RESULTS: There were 9572 eligible visits during which the patient was approached. For universal screening, 40.8% (1915/4692) consented with 6 being newly diagnosed [0.31%, 95% confidence interval (CI): 0.13% to 0.65%]. For targeted screening, 37% (1813/4880) had no testing indication. Of the 3067 remaining, 47.4% (1454) consented with 3 being newly diagnosed (0.22%, 95% CI: 0.06% to 0.55%). Estimated seroprevalence was 0.36% (95% CI: 0.16% to 0.70%). Targeted screening had a higher proportion consenting (47.4% vs. 40.8%, P < 0.002), but a lower proportion of ED encounters with testing (29.7% vs. 40.7%, P < 0.002). CONCLUSIONS: Targeted screening, even when fully implemented with maximally permissive selection, offered no important increase in positivity rate or decrease in tests performed. Universal screening diagnosed more cases, because more were tested, despite a modestly lower consent rate.
Authors: Michael S Lyons; Christopher J Lindsell; Holly K Ledyard; Peter T Frame; Alexander T Trott Journal: Public Health Rep Date: 2005 May-Jun Impact factor: 2.792
Authors: Wayne A Duffus; Kristina Weis; Lynda Kettinger; Terri Stephens; Helmut Albrecht; James J Gibson Journal: AIDS Patient Care STDS Date: 2009-05 Impact factor: 5.078
Authors: Ronald J Lubelchek; Karen A Kroc; David L Levine; Kathleen G Beavis; Rebeca R Roberts Journal: Ann Emerg Med Date: 2011-07 Impact factor: 5.721
Authors: Yvette Calderon; Jason Leider; Susan Hailpern; Robert Chin; Reena Ghosh; Jade Fettig; Paul Gennis; Polly Bijur; Laurie Bauman Journal: AIDS Patient Care STDS Date: 2009-09 Impact factor: 5.078
Authors: Uriel R Felsen; Chinazo O Cunningham; Moonseong Heo; Donna C Futterman; Jeffrey M Weiss; Barry S Zingman Journal: J Acquir Immune Defic Syndr Date: 2017-05-01 Impact factor: 3.731
Authors: Bernard M Branson; Pollyanna R Chavez; Brett Hanscom; Elizabeth Greene; Laura McKinstry; Kate Buchacz; Geetha Beauchamp; Theresa Gamble; Barry S Zingman; Edward Telzak; Tammey Naab; Lisa Fitzpatrick; Wafaa M El-Sadr Journal: Clin Infect Dis Date: 2018-05-02 Impact factor: 9.079
Authors: Michael S Lyons; Vidhya A Kunnathur; Susan D Rouster; Kimberly W Hart; Matthew I Sperling; Carl J Fichtenbaum; Kenneth E Sherman Journal: Clin Infect Dis Date: 2016-02-21 Impact factor: 9.079
Authors: Michelle D Eckerle; Madjimbaye Namde; Carolyn K Holland; Andrew H Ruffner; Kim W Hart; Christopher J Lindsell; Jennifer L Reed; Michael S Lyons Journal: Am J Emerg Med Date: 2015-04-10 Impact factor: 2.469
Authors: Jason S Haukoos; Michael S Lyons; Douglas A E White; Yu-Hsiang Hsieh; Richard E Rothman Journal: Ann Emerg Med Date: 2014-08-13 Impact factor: 5.721
Authors: Uriel R Felsen; Lucia V Torian; Donna C Futterman; Stephen Stafford; Qiang Xia; David Allan; David Esses; Chinazo O Cunningham; Jeffrey M Weiss; Barry S Zingman Journal: AIDS Care Date: 2019-05-30
Authors: Parastu Kasaie; W David Kelton; Rachel M Ancona; Michael J Ward; Craig M Froehle; Michael S Lyons Journal: Acad Emerg Med Date: 2017-11-11 Impact factor: 3.451
Authors: Jessica P Ridgway; Ellen A Almirol; Alvie Bender; Andrew Richardson; Jessica Schmitt; Eleanor Friedman; Nicola Lancki; Ivan Leroux; Nina Pieroni; Jessica Dehlin; John A Schneider Journal: AIDS Patient Care STDS Date: 2018-04-19 Impact factor: 5.078
Authors: Sara Bares; Rebecca Eavou; Clara Bertozzi-Villa; Michelle Taylor; Heather Hyland; Rachel McFadden; Sachin Shah; Mai T Pho; James Walter; Sameer Badlani; John Schneider; Nik Prachand; Nanette Benbow; David Pitrak Journal: Public Health Rep Date: 2016 Jan-Feb Impact factor: 2.792
Authors: Phillip C Moschella; Kimberly W Hart; Andrew H Ruffner; Christopher J Lindsell; D Beth Wayne; Matthew I Sperling; Alexander T Trott; Carl J Fichtenbaum; Michael S Lyons Journal: Am J Public Health Date: 2014-07-17 Impact factor: 9.308